2583 indexable Genomics companies headquartered in United States, ranked by total equity funding and recent funding momentum. Combined disclosed equity funding of $64.9B across 1331 funded companies, including 13 unicorns.
| # | Company | Funding | Valuation | Stage | Latest round | Employees | Founded | Momentum |
|---|---|---|---|---|---|---|---|---|
| 1 |
Senti Bio
Developer of cell and gene therapies for patients living with incurable diseases |
$158M | — | Public | Post IPO May 2026 | 122 | 2016 | ↑ Active |
| 2 |
Lexicon Pharmaceuticals
Developer of small molecule drugs for diffrent health diseases |
$381.3M | — | Public | Post IPO Feb 2026 | 135 | 1995 | ↑ Active |
| 3 |
Guardant Health
Developer of digital sequencing technology for cancer detection |
$557.5M | — | Public | Post IPO Nov 2025 | 1,351 | 2012 | ↑ Active |
| 4 |
Adela
Developer of a platform for detection of cancer |
$108.5M | — | Series A | Series A Apr 2026 | 62 | 2021 | ↑ Active |
| 5 |
Precision BioSciences
Developer of gene editing therapies to treat rare genetic diseases |
$135.7M | — | Public | Post IPO Mar 2026 | 236 | 2006 | ↑ Active |
| 6 |
ClearNote Health
Developer of non-invasive cancer detection methods |
$70M | — | Series D | Series D May 2026 | 45 | 2016 | ↑ Active |
| 7 |
Delfi Diagnostics
Provider of DNA sequencing for cancer detection |
$331.6M | — | Series B | Conventional Debt Dec 2025 | 197 | 2019 | ↑ Active |
| 8 |
Solid Biosciences
Developer of gene therapy platform for Duchenne muscular dystrophy |
$92.5M | — | Public | Post IPO Mar 2026 | 101 | 2014 | ↑ Active |
| 9 |
Cartography Biosciences
Provider of a platform to discover immunotherapeutics |
$57M | — | Series B | Series B May 2026 | 10 | 2020 | ↑ Active |
| 10 |
ReviR Therapeutics
Developer of RNA-based therapeutics for multiple diseases |
$54M | — | Series A | Series A Apr 2026 | 29 | 2021 | ↑ Active |
| 11 |
Aspen Neuroscience
Provider of genomic-based personalised pluripotent stem cell therapy |
$224M | — | Series C | Series C Nov 2025 | 94 | 2018 | ↑ Active |
| 12 |
Antheia
Genetically engineered yeast cells to produce medicinal products |
$96.4M | — | Series C | Series C Jan 2026 | 50 | 2013 | ↑ Active |
| 13 |
Kytopen
Developer of gene delivery systems for cell therapy |
$43.1M | — | Series B | Series B Apr 2026 | 12 | 2017 | ↑ Active |
| 14 |
Arbor Biotechnologies
Provider of genomic technologies and drug discovery platform |
$300M | — | Series C | Series C Oct 2025 | 117 | 2016 | ↑ Active |
| 15 |
Kriya Therapeutics
Developer of therapeutic solutions for the treatment of diabetes |
$617.6M | — | Series D | Series D Jul 2025 | 159 | 2012 | ↑ Active |
| 16 |
Maze Therapeutics
Developer of genetic bio-markers in neurological, metabolic, and renal diseases |
$381M | — | Public | Post IPO Sep 2025 | 111 | 2018 | ↑ Active |
| 17 |
Caris Life Sciences
Unicorn Developer of panomic disease profiling technologies for cancer precision medicine |
$1.1B | $7.8B as of 2021 |
Public | Series D Apr 2025 | 1,339 | 1996 | ↑ Active |
| 18 |
Sirnaomics
Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease |
$267M | — | Public | Post IPO Sep 2025 | 88 | 2007 | ↑ Active |
| 19 |
Affinity Biosensors
Developer of rapid antimicrobial susceptibility testing devices for life sciences |
$31.3M | — | Series B | Post IPO Mar 2026 | 21 | 2006 | ↑ Active |
| 20 |
Tango Therapeutics
Developer of drugs for the treatment of cancer |
$165M | — | Public | Post IPO Oct 2025 | 140 | 2017 | ↑ Active |
| 21 |
Addition Therapeutics
Developer of RNA-mediated genetic medicines |
$106.5M | — | Series A | Series A Dec 2025 | — | 2021 | ↑ Active |
| 22 |
CAMP4
Provider of a drug prediction and development tool for researchers |
$179.6M | — | Public | Post IPO Sep 2025 | 62 | 2018 | ↑ Active |
| 23 |
4D Path
Developer of precision medicines for the treatment of cancer |
$17.1M | — | Series B | Series B May 2026 | 10 | 2016 | ↑ Active |
| 24 |
QurAlis
Developing drugs & CSF cartridge device for treating amyotrophic lateral sclerosis (ALS) |
$143.5M | — | Series B | Series B Aug 2025 | 38 | 2016 | ↑ Active |
| 25 |
Applied DNA Sciences
Developer of botanical-DNA based security and authentication solutions |
$98.6M | — | Public | Post IPO Sep 2025 | 55 | 1983 | ↑ Active |
| 26 |
Cleveland Diagnostics
Developer of diagnostics technology to detect cancer in early stage |
$96.8M | — | Series E | Series E Oct 2025 | 40 | 2013 | ↑ Active |
| 27 |
Aspira Women's Health
Provider of diagnostic solution for ovarian malignancy in women |
$96.7M | — | Public | Post IPO Sep 2025 | 85 | 1993 | ↑ Active |
| 28 |
Ansa Biotechnologies
Provider of DNA synthesis technology using enzymes |
$82M | — | Series B | Series B Oct 2025 | 253 | 2017 | ↑ Active |
| 29 |
Mission Bio
Provider of single cell multiomics platform for genotypic and phenotypic analysis |
$120M | — | Series C | Series C Aug 2025 | 109 | 2014 | ↑ Active |
| 30 |
Phylos Bioscience
Developer of cannabis F1 hybrid seeds and natural THC products |
$28.2M | — | Series B | Series B Dec 2025 | 61 | 2014 | ↑ Active |
| 31 |
NovaScan
Developer of diagnostic platform technology for cancer detection |
$8.1M | — | Series B | Series B Apr 2026 | 16 | 2001 | ↑ Active |
| 32 |
Think Bioscience
Provider of synthetic biology platform to develop small-molecule therapeutics |
$26M | — | Series A | Series A Jan 2026 | 21 | 2019 | ↑ Active |
| 33 |
Volastra
Developer of therapeutics for cancer treatment |
$87.2M | — | Series B | Series B Sep 2025 | 21 | 2019 | ↑ Active |
| 34 |
Remedium Bio
Developer of gene therapies for a broad range of diseases |
$5.6M | — | Series A | Series A May 2026 | 5 | 2020 | ↑ Active |
| 35 |
BridGene Biosciences
Developer of small-molecule drugs for the treatment of cancer |
$50.5M | — | Series B | Series B Oct 2025 | 25 | 2018 | ↑ Active |
| 36 |
Cofactor Genomics
Developer of diagnostic assays using RNA sequencing |
$26.2M | — | Series A | Series A Dec 2025 | 9 | 2009 | ↑ Active |
| 37 |
GreenLight Biosciences
Unicorn Developer of a platform for RNA-based products for life science industry |
$215.1M | $1.2B as of 2021 |
Public | Post IPO Apr 2025 | 287 | 2008 | ↑ Active |
| 38 |
GenoPalate
Provider of personalized diet plans based on the genetic disposition |
$12.4M | — | Series A | Series A Feb 2026 | 15 | 2016 | ↑ Active |
| 39 |
Kiyatec
Develops 3D phenotypic cell-based assays and diagnostic solutions for prediction of patients’ response to cancer drug treatment |
$29.5M | — | Series C | Series C Nov 2025 | 28 | 2005 | ↑ Active |
| 40 |
Sherlock
Provider of a diagnostic platform for DNA and RNA detection |
$111M | — | Acquired | Grant (prize money) Jun 2025 | 33 | 2019 | ↑ Active |
| 41 |
Seek Labs
Developer of a technology for the treatment and diagnostics of infectious diseases. |
$13.6M | — | Series B | Grant (prize money) Feb 2026 | 27 | 2017 | ↑ Active |
| 42 |
Mirvie
Provider of non-invasive diagnostic tests for pregnant women |
$90M | — | Series B | Series B Jul 2025 | 35 | 2019 | ↑ Active |
| 43 |
RareCyte
Developer of technologies for the analysis of rare and single cells in the blood |
$114.3M | — | Series C | Grant (prize money) May 2025 | 54 | 2009 | ↑ Active |
| 44 |
Arpeggio
Provider of drug discovery platform for the treatment of cancer |
$25.4M | — | Series B | Series B Nov 2025 | 8 | 2017 | ↑ Active |
| 45 |
Strand Therapeutics
Provider of platform to deliver mRNA therapeutics for multi functional treatments |
$103.1M | — | Series B | Series B May 2025 | 47 | 2017 | ↑ Active |
| 46 |
Genialis
Developer of end-to-end bioinformatics software solutions |
$15.3M | — | Series A | Series A Dec 2025 | 35 | 2015 | ↑ Active |
| 47 |
Solarea Bio
Innovating microbial solutions for human health, focusing on aging well |
$27.3M | — | Series B | Series B Nov 2025 | 24 | 2017 | ↑ Active |
| 48 |
Rgenta
Developer of RNA-based therapeutics for multiple disorders |
$90M | — | Series A | Series A 2025 | 11 | 2018 | ↑ Active |
| 49 |
Atlas Data
Provider of cloud-based data storage solutions utilizing DNA as a highly durable, low-cost, and permanent data storage medium |
$155M | — | Seed | Seed May 2025 | — | 2025 | ↑ Active |
| 50 |
eGenesis
Developer of a gene transplantation platform for humanizing pig cells |
$481.4M | — | Series D | Series D Sep 2024 | 94 | 2015 | ↑ Active |
Developer of cell and gene therapies for patients living with incurable diseases. The company has developed its proprietary synthetic biology platform to produce cell and gene therapies for cancer treatment. The company's pipeline is comprised of cell therapies engineered with Gene Circuits to target difficult to treat liquid and solid tumors. It offers CAR-NK-based therapies for multiple cancer and tumors.
Developer of small molecule drugs for diffrent health diseases. It uses gene trapping and gene targeting technologies to discover new drug targets and develop small molecule drugs across therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
Developer of digital sequencing technology for cancer detection. The product Guardant360 offers real-time, biopsy-free tumor sequencing for the analysis and identification of tumor-associated treatment options. Also, it has developed analytical tools, including a tumor response map and a mobile-enabled physician portal.
Developer of a platform for detection of cancer. The company has developed a blood test for genome-wide methylation analysis technology to detect kidney cancer and intracranial brain tumors. It allows distinguishing the informative methylated regions of the genome from non-informative regions and targets for sequencing.
Developer of gene editing therapies to treat rare genetic diseases. The company utilizes novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination. The company's pipeline include therapies for Hepatitis B, duchenne muscular dystrophy, and more.
Developer of non-invasive cancer detection methods. It offers a 5-hydroxymethylcytosine-based epigenomic platform and cell-free DNA-based assays to measure biological changes in cells and detect cancers with high mortality rates when they respond best to treatment.
Provider of DNA sequencing for cancer detection. The company's platform uses artificial intelligence and whole genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients with cancer.
Developer of gene therapy platform for Duchenne muscular dystrophy. The lead candidate SGT-001 is Microdystrophin, a synthetic version of the dystrophin gene which stabilizes the muscle membrane and dystrophin-glycoprotein complex. Also, developed a soft wearable device for mobility and help preserve muscle function.
Provider of a platform to discover immunotherapeutics. It provides a platform that combines computational and experimental techniques to profile antigens of cancerous cells and identify targets for immuno-oncology treatments.
Developer of RNA-based therapeutics for multiple diseases. The company is leveraging machine learning technology and innovative RNA techniques to develop medicines for the treatment of cancer, rare genetic disorders, and infectious diseases.
Provider of genomic-based personalized pluripotent stem cell therapy. It offers regenerative cell treatment like dopaminergic neurons for Parkinson's disease and other neurological disorders. It maintains the genetic-based quality control to avoid the mutation of cells used for therapy.
Antheia is focused on developing medicines using its technology. Its technology combines synthetic biology, informatics, and fermentation technology to provide plant-based medicines. It is currently working on engineering the yeast cells genetically to produce natural medicinal products.
Rankings are computed by Radar (Fliar BI) from the Radar company master and are updated periodically. Funding and momentum scores use disclosed equity-funding data only. Figures may lag private rounds. Last updated 2026-06-16.
